News Breaks |
|
|
| September 7, 2012 |
| 07:38 EDT |  | TSRX, CBST, SRPT | American Society for Microbiology to host a conference
Interscience Conference on Antimicrobial Agents & Chemotherapy: ICAAC 2012 to be held in San Francisco on September 7-11. |
|
|
News For TSRX;CBST;SRPT From The Last 14 Days Check below for free stories on TSRX;CBST;SRPT the last two weeks. |
|
|
| May 17, 2013 |
| 05:51 EDT |  | CBST | Stocks with implied volatility movement; CBST CELG
 Subscribe for More Information |
|
| May 16, 2013 |
| 07:29 EDT | | CBST, SRPT | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. |
|
| May 15, 2013 |
| 17:46 EDT |  | CBST | SAC Capital gives quarterly update on stakes
NEW STAKES: Discovery (DISCA), Liberty Global (LBTYA), Liberty Media (LMCA), Norwegian Cruise Line (NCLH), and Cubist (CBST). INCREASED STAKES: Suncor (SU), EQT Corporation (EQT), Amazon.com (AMZN), Visa (V), and GNC Holdings (GNC). DECREASED STAKES: News Corp. (NWSA), Facebook (FB), Sherwin-Williams (SHW), and Avago (AVGO). LIQUIDATED STAKES: Coach (COH), Dover (DOV), and Virgin Media (VMED), . |
|
| 16:00 EDT | | CBST | Optimer calls active following takeover report
Optimer (OPTR) May and June 17 calls are active on 5,600 contracts (500 puts) according to Track Data. Traders are taking positions for large price movement on Cubist (CBST) offered to buy the company for $20 per share, Reuters says. |
|
| 15:54 EDT | | CBST | Optimer up 12.5%, to $16.03 after Reuters report Cubist offered $20 per share
Subscribe for More Information |
|
| 15:53 EDT | | CBST | Cubist offered to buy Optimer for $20 per share, Reuters says
Subscribe for More Information |
|
| May 13, 2013 |
| 16:53 EDT |  | CBST | Optimer gets bids from AstraZeneca, Cubist, Astellas, Bloomberg says
Optimer (OPTR) has received first round bids from AstraZeneca (AZN), Cubist (CBST), and Astellas, reports Bloomberg, citing people familiar with the matter. Shares of Optimer spiked higher following the report, closing up $1.85, or 14.44%, to $14.66. The report notes the company disclosed almost three months ago it was exploring its strategic options. Reference Link |
|
| 15:55 EDT | | CBST | Optimer gets first round bids from AstraZeneca, Cubist, Bloomberg says
Subscribe for More Information |
|
| 08:18 EDT | | TSRX | Trius Therapeutics annoucnes notice of patent applications
Subscribe for More Information |
|
| May 10, 2013 |
| 10:00 EDT |  | TSRX | On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 3D Systems (DDD) initiated with a Buy at Janney Capital... Actavis (ACT) initiated with an Outperform at BMO Capital... Allergan (AGN) initiated with an Outperform at BMO Capital... Emeritus (ESC) initiated with an Outperform at Wells Fargo... Ensign Group (ENSG) initiated with a Market Perform at Wells Fargo... Forest Labs (FRX) initiated with an Underperform at BMO Capital... J2 Global (JCOM) initiated with an Outperform at Wedbush... Mylan (MYL) initiated with an Underperform at BMO Capital... Splunk (SPLK) initiated with a Market Perform at FBR Capital... Teva (TEVA) initiated with an Outperform at BMO Capital... Workday (WDAY) initiated with an Outperform at Oppenheimer... Nuance (NUAN) initiated with an Outperform at Wedbush... Demandware (DWRE) initiated with an Outperform at Wedbush... Synchronoss (SNCR) initiated with an Outperform at Wedbush... Trius Therapeutics (TSRX) initiated with a Buy at Guggenheim... Proto Labs (PRLB) initiated with a Buy at Janney Capital... Stratasys (SSYS) initiated with a Buy at Janney Capital. |
| |
| 07:25 EDT | | TSRX | Trius Therapeutics initiated with a Buy at Guggenheim
Subscribe for More Information |
|
| May 9, 2013 |
| 12:21 EDT | | SRPT | Sarepta climbs after saying documents to be submitted this month
Subscribe for More Information |
|
| 07:29 EDT |  | SRPT | Sarepta reports Q1 EPS (41c), consensus (62c)
Reports Q1 revenue $4.5M, consensus $5.85M. |
|
| May 7, 2013 |
| 16:07 EDT | | TSRX | Trius Therapeutics reports Q1 EPS (38c), consensus (36c)
Reports Q1 revenue $1.73M, consensus $5.51M. |
|
| 13:15 EDT | | SRPT | Options with increasing implied volatility: CVRR SRPT PGH TWO GDI HNZ
Subscribe for More Information |
|
| 08:59 EDT | | SRPT | Sarepta initiates dosing in Phase I study of Marburg virus treatment
Subscribe for More Information |
|
| 08:34 EDT | | CBST | FDA grants fast track desingation for Cubist's late-stage antibiotic candidate
Subscribe for More Information |
|
|
|
|
|
